Lazcluze (Lazertinib Mesylate) Patent Expiration, LOE Window & CMS Spending
Lazcluze (Lazertinib Mesylate) by Johnson & Johnson: FDA Orange Book core substance LOE 2038-04-18 (last listed 2041-08-01), 0 AB generics, $7.8M 2024 CMS Part D & Medicaid spend, and $18,198 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Johnson & Johnson |
| FDA Application & Pathway | N219008 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2038-04-18 |
| Last Listed Patent or Exclusivity Date | 2041-08-01 |
| Orange Book Patents (*PED Extensions) | 9 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $7.8M |
| 2024 Medicare Part D Spend | $7.1M |
| 2024 Medicaid Spend | $661K |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($18,198 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.